We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Atossa Genetics Inc. (ATOS - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Atossa Genetics Inc. is one of 1000 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Atossa Genetics Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ATOS' full-year earnings has moved 9.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ATOS has moved about 9.1% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -8.6% on a year-to-date basis. This means that Atossa Genetics Inc. is outperforming the sector as a whole this year.
Clover Health Investments, Corp. (CLOV - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 5.1%.
In Clover Health Investments, Corp.'s case, the consensus EPS estimate for the current year increased 257.1% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Atossa Genetics Inc. belongs to the Medical - Instruments industry, a group that includes 85 individual companies and currently sits at #82 in the Zacks Industry Rank. On average, stocks in this group have lost 8.8% this year, meaning that ATOS is performing better in terms of year-to-date returns.
On the other hand, Clover Health Investments, Corp. belongs to the Medical Info Systems industry. This 38-stock industry is currently ranked #47. The industry has moved +17.2% year to date.
Investors interested in the Medical sector may want to keep a close eye on Atossa Genetics Inc. and Clover Health Investments, Corp. as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Atossa Genetics Inc. (ATOS - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Atossa Genetics Inc. is one of 1000 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Atossa Genetics Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ATOS' full-year earnings has moved 9.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ATOS has moved about 9.1% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -8.6% on a year-to-date basis. This means that Atossa Genetics Inc. is outperforming the sector as a whole this year.
Clover Health Investments, Corp. (CLOV - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 5.1%.
In Clover Health Investments, Corp.'s case, the consensus EPS estimate for the current year increased 257.1% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Atossa Genetics Inc. belongs to the Medical - Instruments industry, a group that includes 85 individual companies and currently sits at #82 in the Zacks Industry Rank. On average, stocks in this group have lost 8.8% this year, meaning that ATOS is performing better in terms of year-to-date returns.
On the other hand, Clover Health Investments, Corp. belongs to the Medical Info Systems industry. This 38-stock industry is currently ranked #47. The industry has moved +17.2% year to date.
Investors interested in the Medical sector may want to keep a close eye on Atossa Genetics Inc. and Clover Health Investments, Corp. as they attempt to continue their solid performance.